 <h1>Valturna Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>aliskiren / valsartan</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about aliskiren / valsartan. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Valturna.</p><p><i>Applies to aliskiren/valsartan: oral tablet</i></p><h3>Genitourinary</h3><p>Genitourinary side effects have included urinary tract infection (1.4%).  Genitourinary side effects reported for the aliskiren component have included elevated uric acid (0.4%), gout (0.2%), and renal stones (0.2%).  Genitourinary side effects reported for the valsartan component have included impotence.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included fatigue (2.6%) and vertigo (1.1%).  Nervous system side effects reported for the aliskiren component have included headache, dizziness, fatigue, cough, and tonic-clonic seizures in two patients, one of which had a history of seizures and the other had no history given.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included diarrhea (1.4%).  Gastrointestinal side effects reported for the aliskiren component have included diarrhea which increased with increasing dosage and was higher in elderly women, abdominal pain, dyspepsia, and gastroesophageal reflux.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Immunologic side effects have included nasopharyngitis (2.6%) and upper respiratory tract infection (1.1%).  Immunologic side effects reported for the aliskiren component have included nasopharyngitis and upper respiratory tract infection.  There have been postmarketing reports of angioedema requiring airway management and hospitalization associated with aliskiren.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Ocular side effects reported for the aliskiren component have included periorbital edema without respiratory symptoms.<sup>[Ref]</sup></p><h3>General</h3><p>General side effects reported for the aliskiren component have included angioedema (0.06%), and edema involving the face, hands, or whole body (0.4%), and cough (1.1%).  General side effects reported for the valsartan component have included cough (2.6%), and angioedema.<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects reported for the aliskiren component have included rash (1%).<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Musculoskeletal side effects reported for the aliskiren component have included back pain.  Musculoskeletal side effects reported for the valsartan component have included asthenia and muscle cramps.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects reported for the valsartan component have included paresthesia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects reported for the valsartan component have included sinusitis and pharyngitis.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included small mean decreases from baseline in red blood cell (RBC) count, hemoglobin, and hematocrit in both monotherapy and combination therapy.</p><p></p><p>Postmarketing hematologic side effects have included increased blood creatinine.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Hepatic side effects have included elevations in blood urea nitrogen (BUN) and creatinine (less than 1%).<sup>[Ref]</sup></p><h3>Metabolic</h3><p>There have been postmarketing reports of peripheral edema associated with aliskiren.</p><h3>Dermatologic</h3><p>Postmarketing reports have included severe cutaneous adverse reactions, including Stevens Johnson syndrome and toxic epidermal necrolysis.</p><p id="ref_1">1. "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. "Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. "Product Information. Valturna (aliskiren-valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about Valturna (aliskiren / valsartan)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>9 Reviews</li>
<li>Drug class: miscellaneous antihypertensive combinations</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Blood Pressure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>